The effect of doxycycline on canine hip osteoarthritis: design of a 6-months clinical trial.
10.4142/jvs.2009.10.3.239
- Author:
Korakot NGANVONGPANIT
1
;
Peraphan POTHACHAROEN
;
Niyada SUWANKONG
;
Siriwan ONG-CHAI
;
Prachya KONGTAWELERT
Author Information
1. Bone and Joint Research Laboratory, Department of Veterinary Biosciences and Public Health, Chiang Mai University, Chiang Mai 50100, Thailand.
- Publication Type:Original Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
- Keywords:
biomarkers;
canine;
chondroitin sulfate;
doxycycline;
osteoarthritis
- MeSH:
Animals;
Biological Markers/blood;
Dog Diseases/*drug therapy;
Dogs;
Doxycycline/*therapeutic use;
Female;
Hyaluronic Acid/blood;
Joints/drug effects;
Lameness, Animal/drug therapy;
Male;
Osteoarthritis, Hip/drug therapy/*veterinary;
Time Factors;
Treatment Outcome
- From:Journal of Veterinary Science
2009;10(3):239-247
- CountryRepublic of Korea
- Language:English
-
Abstract:
Twenty-five dogs were included in a randomized, double-blind trial to assess the efficacy of doxycycline (DOX) orally administered twice a day at 4 mg/kg/day (n = 12) for the treatment of osteoarthritis of the hip. Chondroitin sulfate (CS; 525 mg/day) was used as a positive control (n = 13). Dogs were re-examined monthly for 6 months after initiation of treatment. The assessment protocol included clinical score, radiographic findings and serum osteoarthritis biomarkers. Dogs treated with DOX showed statistically significant improvements (p < 0.05) in lameness, joint mobility, pain on palpation, weight-bearing and overall score at 2, 6, 4, 4 and 4 months, respectively, after treatment. Biomarker levels of CS-WF6 epitope and hyaluronan were significantly increased and decreased (p < 0.05) at 2 and 3 months after treatment compared to pretreatment. These results showed that DOX had a positive therapeutic effect in dogs with osteoarthritis.
